James Mulay Sells 24,165 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 24,165 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the completion of the sale, the director directly owned 24,165 shares in the company, valued at approximately $1,816,241.40. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

James Mulay also recently made the following trade(s):

• On Monday, June 15th, James Mulay sold 1,964 shares of CG Oncology stock. The shares were sold at an average price of $60.12, for a total transaction of $118,075.68.
• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00.

CG Oncology Trading Up 1.7%

Shares of NASDAQ:CGON opened at $73.00 on Thursday. The firm’s 50 day moving average is $65.22 and its two-hundred day moving average is $61.01. The firm has a market capitalization of $6.44 billion, a P/E ratio of -31.33 and a beta of 0.22. CG Oncology, Inc. has a 52 week low of $23.65 and a 52 week high of $77.00.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.45 million. Analysts predict that CG Oncology, Inc. will post -2.89 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CGON. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Royal Bank Of Canada increased their target price on shares of CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Wedbush boosted their price target on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research note on Monday, May 18th. Finally, Wolfe Research assumed coverage on shares of CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.73.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of CGON. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CG Oncology in the 4th quarter worth approximately $27,000. NFSG Corp bought a new position in shares of CG Oncology in the first quarter valued at $34,000. Comerica Bank boosted its stake in shares of CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares in the last quarter. Fifth Third Bancorp bought a new stake in shares of CG Oncology during the 1st quarter worth $74,000. Finally, KBC Group NV acquired a new position in shares of CG Oncology in the 1st quarter worth $78,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.